Talk:Belantamab mafodotin

From WikiProjectMed
Jump to navigation Jump to search

FDA IND withdrawn for Belantamab Mafodotin

This page should be updated to indicate that GSK withdrew the US marketing application for relapsed/refractory multiple myeloma indication per the FDA's request after the DREAMM-3 trial. 156.111.108.150 (talk) 17:43, 5 June 2023 (UTC)[reply]